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Interstitial lung disease (ILD), particularly idiopathic pulmonary fibrosis (IPF), has a poor prognosis. 
Corticosteroids are widely used in the treatment of acute exacerbation of ILD (AE-ILD). This study 
aimed to clarify the causes of AE-ILD, determine the efficacy of corticosteroids for treating AE-ILD, 
and detect differences in the mortality rate among subgroups of ILD. This was an observational 
retrospective single-center study. Patients with ILD who presented to the emergency department 
with acute respiratory symptoms from January 1, 2016, to December 31, 2018, were included. 
Patients with AE-ILD were classified into two groups depending on the prednisolone dose: low dose (0 
to 1.0 mg/kg) or high dose (> 1.0 mg/kg). Mortality rates between patients with and without IPF were 
compared. This study included 182 patients with AE-ILD, including IPF (n = 117) and non-IPF (n = 65). 
Multivariate Cox regression analysis showed that corticosteroid dose (HR: 0.221, CI: 0.102–0.408, 
P < 0.001), initial P/F ratio (HR:0.995, CI:0.992–0.999, P = 0.006), and mechanical ventilation within 
3 days of hospitalization (HR:4.205, CI:2.059–8.589, P < 0.001) were independent risk factors for 
mortality in patients with AE-ILD. This study showed that outcomes improve with higher doses of 
corticosteroids (> 1 mg/kg prednisolone) in patients with AE-non-IPF-ILD. However, this was not the 
case in patients with AE-IPF.
Interstitial lung disease (ILD) is a diffuse parenchymal lung disease characterized by inflammation or fibrosis of 
the interstitium, alveoli, or terminal bronchioles, with etiologies ranging from rheumatologic or environmental 
to  idiopathic1. It has been estimated that approximately 100,000 hospital admissions per year and 15% of all 
pulmonologist appointments are due to  ILD2. The common feature across different ILD types, irrespective of the 
clinical presentation, disease progression, or prognosis, is fibrotic destruction of the lung  parenchyma3. An acute 
exacerbation of ILD (AE-ILD) can occur at any time, and is associated with significant morbidity and mortality.
Idiopathic pulmonary fibrosis (IPF) is the most severe form of ILD. Acute exacerbation of IPF (AE-IPF) por-
tends an even worse prognosis, with earlier studies reporting a mortality of 50–80% and a median survival time 
of 3–4  months4,5. However, more recent studies have suggested slightly higher survival rates: 1-month survival 
rate of 66% (range: 47–85%); 3-month survival rate of 41% (range: 0–54%); and survival to hospital discharge of 
44% (4–77%)6. A study conducted in Japan has even reported survival rates of over 70% in patients treated with 
cyclosporin A or high-dose  corticosteroids7. Approximately 20% of patients with IPF will experience AE-IPF 
over the course of their disease, and about one-fifth of these patients will have more than one AE-IPF  episode4–6; 
thus, AE is now recognized as a relatively common  event7. Although AE has been mainly described in patients 
with IPF, the presentation and consequences of AE appear to be similar in other ILDs. While there is no cohesive 
definition of AE for ILDs other than IPF, criteria similar to those of AE-IPF are often  used1. Additionally, AE-ILD 
has been associated with decreased survival in patients with any connective tissue disease-related  ILD8. Although 
AE-IPF is being increasingly recognized and perceived as a severe event with high associated mortality, there is 
only a limited amount of clinical data on AE-ILD in non-IPF  ILD9. Some studies have attempted to identify risk 
factors common to all forms of AE-ILD; however, their results have often been  inconsistent1. In IPF, low forced 
vital capacity (FVC), low total lung capacity, decreased 6-min walk distance, pulmonary hypertension, baseline 
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hypoxemia, low diffusing capacity of the lung for carbon monoxide  (DLCO), increased dyspnea, and no history 
of smoking are all associated with an increased risk of  exacerbation10,11. Nevertheless, previous sufficient case 
series have failed to confirm these associations.
High-dose corticosteroids, sometimes administered as pulse therapy (with or without immunosuppressive 
agents) in combination with broad-spectrum antimicrobial agents, have been used most commonly in patients 
with AE-ILD. This is the recommended treatment according to recent international treatment guidelines for 
 IPF12. However, the efficacy of this therapy is uncertain, and survival is still very  low4.
The aim of this study was to clarify the causes of AE-ILD and the risk factors associated with mortality, par-
ticularly corticosteroid responsiveness, in patients with AE-ILD admitted to the emergency department (ED).
Results
Patients recruitment. We reviewed medical records and all chest computed tomography (CT) scans of 
patients who were diagnosed with ILD and presented to the ED with symptoms of dyspnea at the Severance 
Hospital between January 2016 and December 2018. A total of 535 patients were initially screened and 330 were 
excluded for the following reasons: (1) fluid overload, (2) congestive heart failure, (3) pulmonary embolism, 
(4) dyspnea unrelated to respiratory disease, and (5) worsening symptoms for more than 1 month. Finally, 205 
patients with AE-ILD were enrolled. A further 23 cases were excluded because of insufficient data, including lack 
of pulmonary function test results within 6 months before the ED visit and unavailable baseline arterial blood 
gas values, resulting in 182 selected patients. In June 2019, all subjects were reevaluated by multidisciplinary 
discussion using patient history, physical examination, laboratory results, chest high-resolution CT (HRCT), 
and histopathological findings. The final diagnoses were categorized as IPF and non-IPF ILD; the latter diag-
nosis included connective tissue disease-associated ILD, idiopathic nonspecific interstitial pneumonia, crypto-
genic organizing pneumonia, sarcoidosis, hypersensitivity pneumonitis, and other conditions (toxic humidifier 
sterilizers-induced ILD and amiodarone-induced ILD). Among the included patients, 117 had IPF and 65 had 
non-IPF ILD (Fig. 1).
Patient characteristics and microbiology. A total of 182 patients were included in the study, and the 
baseline characteristics of the study sample are shown in Table 1. The mean patient age was 68.7 ± 11.6 years. 
Among the total patients, 117 (64.3%) had IPF, 67.0% were male, and 45.4% had a history of smoking. Patients in 
the IPF group were more commonly exposed to smoking (57.9%) than those in the non-IPF ILD group (21.7%). 
FVC and forced expiratory volume in the first second  (FEV1) were significantly higher in the non-IPF ILD group 
compared to the IPF group.
The mean dose of prednisolone was 1.0 mg/kg in the IPF group and 1.1 mg/kg in the non-IPF ILD group. 
The total mortality was 40 cases (22.0%), with 30 cases (25.6%) in the IPF group and 10 cases (15.4%) in the 
non-IPF group.
Table 2 shows the comparison between the triggered AE-ILD and non-triggered AE-ILD groups. The trig-
gered AE-ILD group had lower P/F ratios and higher prednisolone doses and lactate levels. The mortality was 
11 cases (22%) in the triggered group and 12 cases (15.8%) in the non-triggered group; however, the difference 
was not statistically significant (P = 0.377).
Table 3 shows the microbiologic analysis of the triggered AE-ILD group. Bacterial infection was dominant in 
both IPF (23.4%) and non-IPF (15.2%) ILD groups. Viral infection was the second most common trigger in the 
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IPF group, while fungal infection (e.g. Pneumocystis jiroveci pneumonia) was the second most common trigger 
in the non-IPF ILD group (13.5%).
Survival outcomes. Table  4 shows the comparison of characteristics between survivors and non-survi-
vors. Forty (22%) patients out of 182 died within 90 days, and most were male (70%). The non-survivor group 
showed a trend of lower  FEV1, DLco, and P/F ratio. Prednisolone was prescribed at a higher dose in the survivor 
group (1.1 ± 0.9) than in the non-survivor group (0.9 ± 0.6), but this was not statistically significant. The rate of 
mechanical ventilation was more than three-fold higher in the non-survivor group (42.5%) than in the survivor 
group (12.7%), and this was statistically significant. The use of vasopressors in the first 3 hospitalization days 
was higher in the non-survivor group (22.5% compared to 12.0% in the survivor group). Comparisons between 
survivors and non-survivors within the IPF group (e-Table 1) and within the non-IPF group (e-Table 2) yielded 
equivalent results.
Table 5 shows the risk factors related to mortality, which were initial P/F ratio (HR: 0.995, CI: 0.992–0.999, 
P = 0.006), high-dose of prednisolone (HR: 0.221, CI: 0.102–0.480, P < 0.001), and need for mechanical ventila-
tion in the first 3 hospitalization days (HR: 4.205, CI: 2.059–8.589, P < 0.001).
Kaplan–Meier estimates of 90-day mortality according to corticosteroid dose are shown in Fig. 2.
The survival rate was significantly higher when the prednisolone dose was higher than 1 mg/kg in the total 
sample of AE-ILD patients (Fig. 2A, log-rank test, P = 0.003). The same results were observed in the non-IPF 
ILD group (Fig. 2C, log-rank test, P = 0.001). In the IPF group, however, the 90-day mortality analysis was not 
statistically significant (Fig. 2B, log-rank test, P = 0.142). e-Fig. 1 shows that survival rates of the triggered and 
non-triggered AE-ILD groups according to corticosteroid dose were not significantly different. The main cause 
Table 1.  Baseline characteristics of patients with acute exacerbation of IPF and non-IPF ILD. Data are 
presented as mean and standard deviation, median and interquartile range, or frequency (%). IPF idiopathic 
pulmonary fibrosis, ILD interstitial lung disease, FVC forced vital capacity, FEV1 forced expiratory volume in 
1 s, DLco diffusing capacity of carbon monoxide, P/F ratio partial pressure of oxygen in arterial blood  (PaO2)/
fraction of inspired oxygen  (FiO2) ratio, GAP score system gender (G), age (A), physiology (P), AE acute 
exacerbation, CAOD coronary artery occlusive disease, NTM non-tuberculous mycobacterium, COPD chronic 
obstructive lung disease, Old TB previous tuberculosis, CRP C-reactive protein.
Variable Total IPF Non-IPF P-value
Total patients 182 117 65
Age, years 68.7 ± 11.6 69.4 ± 9.9 67.4 ± 14.1 0.27
Sex, men 122 (67.0) 94 (80.3) 28 (43.1)  < 0.001
Smoking exposure, n (%)
Never 95 (54.6) 48 (42.1) 47 (78.3)  < 0.001
Former 77 (44.3) 64 (56.1) 13 (21.7)
Current 2 (1.1) 2 (1.8) 0 (0.0)
Pack-years 35.0 (20.0–48.5) 35.0 (20.0–50.0) 25.0 (20.0–40.0) 0.09
FVC % predicted 60.0 (46.0–74.0) 57.0 (41.0–69.0) 67.0 (55.0–80.0) 0.003
FEV1% predicted 71.0 (56.0–85.0) 67.0 (50.5–80.0) 75.5 (61.0–92.0) 0.02
DLCO, % predicted 47.0 (35.0–59.0) 44.0 (31.0–60.0) 49.0 (37.3–58.0) 0.11
Initial P/F ratio 223.4 (158.0–310.0) 220.0 (148.0–291.7) 233.9 (179.6–339.3) 0.29
GAP score 4 (4.0, 6.0) 4 (3.0, 4.0) 4 (3.75, 5.0) 0.16
Prednisolone (mg/kg) 1.0 ± 0.9 1.0 ± 0.8 1.1 ± 0.9 0.20
Previous AE history 60 (33.0) 43 (36.8) 17 (26.2) 0.20
Anti-fibrotics 54 (29.7) 54 (46.2) 0 (0.0)  < 0.001
Supplemental  O2 37 (20.3) 28 (23.9) 9 (13.8) 0.19
Prednisolone before AE 91 (50.0) 49 (41.9) 42 (64.6) 0.97
Medical history, n (%)
Hypertension 33 (18.1) 25 (21.4) 8 (12.3) 0.13
Diabetes mellitus 32 (17.6) 24 (20.5) 8 (12.3) 0.16
CAOD 19 (10.4) 13 (11.1) 6 (9.2) 0.69
NTM 7 (3.8) 4 (3.4) 3 (4.6) 0.69
Old TB 11 (6.0) 8 (6.8) 3 (4.6) 0.55
COPD 12 (6.6) 6 (5.1) 6 (9.2) 0.29
Malignancy 36 (19.8) 21 (17.9) 15 (23.1) 0.41
Use of vasopressors within 3 days 26 (14.3) 19 (16.2) 7 (10.8) 0.31
Need for mechanical ventilator 35 (19.2) 24 (20.5) 11 (16.9) 0.56
CRP (mg/L) 70.5 (21.0–140.0) 65.0 (21.0–136.0) 78.0 (27.0–140.0) 0.33
90 day-mortality 40 (22.0) 30 (25.6) 10 (15.4) 0.21
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of death was respiratory failure caused by AE-ILD (n = 24), followed by pneumonia (n = 10) and combined lung 
cancer progression (n = 6).
Discussion
This retrospective study showed that high doses of corticosteroids are beneficial in most cases of AE-ILD, espe-
cially in cases of AE-non-IPF ILD, but not in cases of AE-IPF. Survival improved when doses of prednisolone 
higher than 1 mg/kg were administered.
The immediate outcome of AE is very poor; the median survival is 2.2 months from onset, and half of the 
patients die during  hospitalization4,6. Furthermore, about 50% of patients need admission to an intensive care 
 unit4. However, the optimal treatment for AE-IPF remains undetermined. A recent retrospective study showed 
that pirfenidone combined with corticosteroids and recombinant human thrombomodulin may improve survival 
in patients with AE-IPF (55% in patients with pirfenidone vs 34% in control group, p = 0.042)13. Most  experts14 
administer systemic corticosteroids with or without immunosuppressants, but the various drug regimens used 
in these two treatment approaches have not been evaluated in randomized controlled trials. Hence, the recom-
mendation of corticosteroid treatment is based on low-quality  evidence12. However, most patients are treated 
with high-dose immunosuppression therapy, typically with pulses of 500–1000 mg of methylprednisolone daily 
for 3  days3,6. The 2018 Japanese IPF treatment guidelines suggest that patients with AE-IPF should be treated with 
corticosteroids, including pulse  therapy15. This is contradicted by the results of Mengshu et al.16 who reported that 
Table 2.  Comparison of baseline characteristics between triggered and non-triggered AE-ILD groups. 
Data are presented as mean and standard deviation, median and interquartile range, or frequency (%). IPF 
idiopathic pulmonary fibrosis, AE-ILD acute exacerbation of interstitial lung disease, FVC forced vital capacity, 
DLco diffusing capacity of carbon monoxide, P/F ratio partial pressure of oxygen in arterial blood  (PaO2)/
fraction of inspired oxygen  (FiO2) ratio, CRP C-reactive protein.
Variable Triggered group Non-triggered group P-value
Total patients, n 50 81
Age, years 71.5 (60.8, 77.0) 72 (64.0, 78.0) 0.271
Sex, male 34 (68) 45 (55.6) 0.318
IPF 31 (62) 42 (51.9) 0.454
Initial P/F ratio 217.2 (160.3, 285.8) 253.6 (188.7, 400.0) 0.017
FVC (%), predicted 60 (47.0, 73.0) 62.0 (51.5, 78.5) 0.623
DLco (%), predicted 50.0 (33.3, 66.8) 49.0 (36.8, 58.3) 0.749
Prednisolone (mg/kg) 1.1 (0.5, 1.5) 0.6 (0.2, 1.2) 0.011
CRP (mg/L) 68.5 (28.5, 145.5) 78.5 (28.4, 159.8) 0.437
Lactate (mmol/L) 1.6 (1.3, 2.7) 1.4 (1.0, 1.9) 0.024
Use of vasopressors within 3 days 7 (14) 15 (19.7) 0.407
Need for mechanical ventilator 11 (22) 24 (29.6) 0.402
90-day mortality 11 (22) 12 (15.8) 0.377
Table 3.  Microbiologic results in the triggered AE-ILD group. AE-ILD acute exacerbation of interstitial lung 
disease. a Metapneumovirus, Influenza virus, Coronavirus, Rhinovirus, and RSV.
Microbiology, n Total (n = 131) IPF (n = 74) Non-IPF ILD (n = 57)
Negative results, % 81 (61.8) 46 (62.2) 35 (61.4)
Bacterial infection, % 28 (21.4) 18 (24.3) 10 (17.5)
Pseudomonas aeruginosa 7 (5.3) 5 (6.8) 2 (3.5)
Mycoplasma 6 (4.6) 5 (6.8) 1 (1.8)
Legionella 6 (4.6) 4 (5.4) 2 (3.5)
Klebsiella  pneumoniae 5 (3.8) 2 (2.7) 3 (5.4)
Stenotrophomonas maltophilia 1 (0.7) 1 (1.4) 0 (0)
Streptococcus pneumoniae 1 (0.7) 1 (1.4) 0 (0)
Acinetobacter baumannii 1 (0.7) 0 (0) 1 (1.8)
Serratia marcescens 1 (0.7) 0 (0) 1 (1.8)
Viral  infectiona, % 10 (7.0) 7 (9.5) 3 (5.4)
Fungal infection, % 12 (9.2) 3 (4.2) 9 (15.8)
Pneumocystis jiroveci 11 (8.4) 2 (2.7) 9 (15.8)
Aspergillus 1 (0.7) 1 (1.4) 0 (0)
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Table 4.  Comparison of characteristics between survivors and non-survivors in patients with acute 
exacerbation of ILD. Data are presented as mean and standard deviation, median and interquartile range, 
or frequency (%). ILD interstitial lung disease, FVC forced vital capacity, FEV1 forced expiratory volume 
in 1 s, DLco diffusing capacity of carbon monoxide, P/F ratio partial pressure of oxygen in arterial blood 
 (PaO2)/fraction of inspired oxygen  (FiO2) ratio, GAP score system gender (G), age (A), physiology (P), AE 
acute exacerbation, CAOD coronary artery occlusive disease, IPF idiopathic pulmonary fibrosis, NTM non-
tuberculous mycobacterium, COPD chronic obstructive lung disease, Old TB previous tuberculosis, CRP 
C-reactive protein.
Variable Total Survivors Non-survivors P-value
Total patients 182 142 (78.0) 40 (22.0)
Age, years 68.7 ± 11.6 69.0 ± 11.7 67.6 ± 11.5 0.52
Sex, men 122 (67.0) 94 (66.2) 28 (70.0) 0.65
Smoking exposure, no. (%)
Never 95 (54.6) 72 (53.3) 23 (59.0) 0.65
Former 77 (44.3) 61 (45.2) 16 (41.0)
Current 2 ( 1.1) 2 ( 1.5) 0 ( 0.0)
Pack-years 35.0 (20.0–48.5) 35.0 (20.0–50.0) 35.0 (18.0–40.0) 0.38
FVC % predicted 60.0 (46.0–74.0) 60.0 (47.0–75.0) 60.0 (45.0–70.0) 0.52
FEV1% predicted 71.0 (56.0–85.0) 72.0 (56.0–85.0) 68.0 (52.0–80.0) 0.43
DLCO, % predicted 47.0 (35.0–59.0) 49.0 (37.0–61.5) 36.5 (29.5–54.0) 0.14
Initial P/F ratio 223.4 (158.0–310.0) 236.4 (158.9–316.7) 210.5 (149.6–279.0) 0.32
GAP score 4 (4.0, 6.0) 4 (3.75, 5.0) 4 (3.0, 4.0) 0.16
Prednisolone (mg/kg) 1.0 ± 0.9 1.1 ± 0.9 0.9 ± 0.6 0.45
Previous AE history 60 (33.0) 48 (33.8) 12 (30.0) 0.59
Anti-fibrotics 54 (29.7) 46 (32.4) 8 (20.0) 0.87
Supplemental  O2 37 (20.3) 29 (20.4) 8 (20.0) 0.29
Prednisolone before AE 91 (50.0) 73 (51.4) 18 (45.0) 0.29
Medical history, n (%)
Hypertension 33 (18.1) 23 (16.2) 10 (25.0) 0.20
Diabetes mellitus 32 (17.6) 27 (19.0) 5 (12.5) 0.34
CAOD 19 (10.4) 17 (12.0) 2 (5.0) 0.20
IPF 117 (64.3) 87 (61.3) 30 (75.0) 0.11
NTM 7 (3.8) 6 (4.2) 1 (2.5) 0.62
Old TB 11 (6.0) 10 (7.0) 1 (2.5) 0.29
COPD 12 (6.6) 11 (7.7) 1 (2.5) 0.24
Malignancy 36 (19.8) 27 (19.0) 9 (22.5) 0.62
CRP (mg/L) 70.5 (21.0–140.0) 62.4 (21.0–139.0) 81.5 (35.0–144.5) 0.22
Need for mechanical ventilator 35 (19.2) 18 (12.7) 17 (42.5)  < 0.001
Use of vasopressors within 3 days 26 (14.3) 17 (12.0) 9 (22.5) 0.09
Table 5.  Cox regression analysis of risk factors related to 90-day mortality in AE-ILD. AE-ILD acute 
exacerbation of interstitial lung disease, FVC forced vital capacity, DLco diffusing capacity of carbon monoxide, 




HR 95% CI p-value HR 95% CI p-value
Age, years 0.993 0.968–1.019 0.603 0.989 0.957–1.009 0.200
Sex, male 1.228 0.624–2.415 0.552 0.777 0.377–1.599 0.493
Initial P/F ratio 0.998 0.998–1.001 0.241 0.995 0.992–0.999 0.006
FVC (%), predicted 0.994 0.975–1.014 0.540
DLco (%), predicted 0.976 0.952–1.001 0.059
Prednisolone > 1 mg/kg 0.380 0.193–0.747 0.005 0.221 0.102–0.480  < 0.001
Use of vasopressors within 3 days 1.852 0.881–3.890 0.104 1.451 0.630–3.340 0.382
Need for mechanical ventilator 3.877 2.068–7.267  < 0.001 4.205 2.059–8.589  < 0.001
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:5762  | https://doi.org/10.1038/s41598-021-85539-1
www.nature.com/scientificreports/
high doses of corticosteroids are not beneficial for AE-ILD patients, and that the clinical outcomes of patients 
with AE-IPF mainly depend on the underlying clinical condition and the extent of lung injury from the AE. 
Thus, there remains a lack of consensus regarding proper treatment of AE-ILD.
Feghali-Bostwick et al.17 showed that patients with IPF frequently have autoantibodies and self-reactive CD4 
T cells, thus fulfilling the diagnostic criteria for an autoimmune  disease18. Moreover, there is a component of 
inflammation in AE-IPF19. Therefore, some patients respond to  corticosteroids20. However, a recent study from 
Figure 2.  Kaplan–Meier survival curves according to corticosteroid use in (A) total patients; (B) patients with 
IPF; (C) patients with non-IPF ILD.
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2020 showed no evidence that corticosteroids improve the outcome of patients with AE-IPF admitted to the 
hospital; furthermore, the results indicated that corticosteroid use following an exacerbation may contribute to 
reduced overall  survival21. Our study showed the same results in AE-IPF cases.
The 90-day mortality rate in this study was relatively low (25.6% in the IPF group and 15.4% in the non-IPF 
ILD group) compared to other studies (mortality rate: 50%–80%)10,22. Initial P/F ratio was a statistically significant 
predictor of mortality in this study, with a lower P/F ratio predicting a higher mortality rate. The patients in our 
study were mainly diagnosed with mild ARDS (median P/F ratio: 223.4), and pirfenidone was administered in 
41.6% (n = 54) of IPF patients before AE. A higher survival rate has been reported for patients with AE-IPF who 
were administered pirfenidone (55%) compared to those not administered pirfenidone (34%; p = 0.042)13. Recent 
developments in ARDS and sepsis management, as well as the use of high corticosteroid doses, may contribute 
to reduced mortality rates in this patient group.
Non-IPF ILD is also associated with autoimmunity, and thus has potential to respond well to corticosteroid 
treatment. According to the abovementioned mechanism of ILD, it could be speculated that corticosteroids 
would be effective in cases of AE-non-IPF ILD, but not in cases of AE-IPF.
AE-ILD can be precipitated by a variety of  factors1. Viral infections, air pollution, aspiration, transfusions, 
drugs, or surgery, all leading to acceleration of the fibro-proliferative response, have been postulated as triggers 
of AE-ILD. However, the specific factors that cause some patients with ILD and not others to develop AE are 
 unknown3,23. Although an infectious trigger could explain why some patients develop AE and others do not, 
no firm associations between bacterial or viral infections (including Epstein-Barr virus, cytomegalovirus, and 
human herpesvirus 8) and AE have been  identified6. In our study, patients were classified as triggered and non-
triggered AE-ILD based on their bacterial, fungal, or viral specimens within 48 h of ED visit. While samples 
could not be collected from 51 patients, 131 out of 182 patients met the above conditions. Our study identified 
50 cases of AE-ILD triggered by bacterial, fungal, or viral infections. These patients had a worse survival outcome 
(90-day mortality of 22% compared to 15.8% in the non-triggered AE cases), although the difference was not 
statistically significant. However, triggered AE-ILD cases showed a more severe clinical course, including lower 
P/F ratios and higher lactate levels. Depending on the severity of the disease, fluid resuscitation, antibiotic use, 
initial ventilator care, sepsis management, and corticosteroid therapy could be needed.
Huie et al. suggested that patients with IPF have a lower survival rate after an acute respiratory decline as com-
pared to patients with non-IPF fibrotic  disease24. Pathophysiologically, AE-ILD resembles an acute lung injury, 
which presents histopathologically as diffuse alveolar damage in most  cases25. A number of factors (including 
low baseline FVC and  DLCO, extensive CT abnormalities and the involvement pattern, low oxygenation, and high 
bronchoalveolar lavage fluid neutrophil and lymphocyte percentages at the time of AE) have been reported as 
associated with survival of patients with AE-IPF3,26,27. However, this study could not demonstrate the significance 
of the radiologic and cellular pattern of bronchoalveolar lavage fluid because of a small sample size.
Patients who required mechanical ventilation from the beginning had a significantly higher mortality rate, 
possibly due to individual differences in the response to oxygen and steroid therapy in the setting of AE. Further 
studies are needed to assess individual differences in the response to oxygen and steroid therapy.
The present study had several limitations. First, this study analyzed data of a single tertiary center. Second, 
although we tried to obtain complete data by reviewing medical records, not all patients underwent a complete 
examination (e.g., missing microbiologic studies) at the initial visit to the ED. Third, we could not analyze long-
term complications of corticosteroid therapy; therefore, we could not identify whether their use led to adverse 
outcomes such as opportunistic infections.
Despite the limitations, this study provides useful evidence for proper initial management and for decision-
making regarding corticosteroid use in patients with AE-non-IPF ILD. Determining the corticosteroid dose 
and the administration modality (pulse therapy or routine high-dose steroids) is always difficult because of the 
potential side effects of corticosteroids. A larger-sample prospective study of patients with AE-ILD is, therefore, 
needed to address these limitations.
Methods
Study design and sample. This study was conducted retrospectively in a tertiary care hospital in South 
Korea.
The following clinical and laboratory data were collected from medical records: age, sex, smoking history, 
pulmonary function test results within 6 months before presenting to the ED, underlying diseases, ratio of initial 
partial pressure of oxygen in arterial blood  (PaO2) to fraction of inspired oxygen  (FiO2; P/F ratio), gender-age-
physiology (GAP) index score, prednisolone dose, serum concentrations of C-reactive protein (CRP) and lactate, 
and date of death. An ever smoker was defined as a person who had smoked at least 100 cigarettes or cigars 
during the course of their life.
The research protocol was approved by the Institutional Review Board of Severance Hospital, South Korea 
(IRB No. 4–2020-0398). The study design was approved by the appropriate ethics review boards. The requirement 
to obtain informed patient consent was waived by the IRB.
Definitions. In this study, AE-IPF was defined as a clinically significant respiratory deterioration developing 
typically within less than 1 month, accompanied by new radiologic abnormalities on HRCT (e.g., diffuse bilat-
eral ground-glass opacification), and with an absence of other obvious clinical causes such as fluid overload, con-
gestive heart failure, or pulmonary embolism. This is in accordance with the official American Thoracic Society/
European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society IPF  guidelines10.
This new definition promotes discrimination between a triggered form of AE-IPF (e.g., infectious, postpro-
cedural/postoperative, or toxic) and an idiopathic form of AE-IPF, in which no trigger is  identified5,10. Regarding 
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other AE-ILDs, it is more challenging to establish the specific diagnoses. The most important element for diag-
nosing AE-ILDs is the HRCT, which must be performed when patients are clinically stable. The typical HRCT 
findings in AE-ILD are newly developed bilateral alveolar infiltrates and ground-glass opacification with or 
without  consolidation6,12. Since there is no definition of AE in non-IPF ILD cases, the definition of AE-IPF was 
applied.
The GAP score was calculated for all patients (IPF and non-IPF) based on sex (0–1 points), age (0–2 points), 
FVC (0–2 points), and  DLCO (0–3 points), and classified into stages I (0–3 points), II (4–5 points), or III (6–8 
points), as previously  described28. Outcome measures were determined based on the medical record review. The 
primary outcome measure was 90-day mortality.
Treatment protocol and steroid dosage. For patients diagnosed with AE-ILD in the ED, blood tests 
(including serum inflammatory markers and routine chemistry), microbiologic cultures, and chest CT scans 
were initially performed. Bronchoscopy with bronchoalveolar lavage, which is an invasive diagnostic procedure, 
was not routinely performed initially due to poor patient tolerance.
In our institution, the main treatment for AE-ILD is the administration of corticosteroids together with 
effective antibiotics. Additionally, we aim for symptom palliation with supplemental oxygen therapy, mechanical 
ventilation when needed, acute respiratory distress syndrome (ARDS) therapy, and shock management.
Corticosteroids are usually administered at doses ranging from 0.5 to 2 mg/kg, depending on the clinical situ-
ation. Steroid pulse therapy was not usually applied except for cases of vasculitis or dermatomyositis-associated 
rapid progressive ILD.
Statistical analysis. Baseline characteristics, including demographics, baseline pulmonary function, res-
piratory parameters, hematologic data, serum CRP and lactate, and survival, were compared between patients 
with IPF and patients with non-IPF ILD according to corticosteroid dose. Categorical variables were compared 
using Pearson’s chi-square test and are reported as numbers and percentages. Continuous variables were com-
pared using logistic regression models. Continuous variables with normal distributions are reported as mean 
and standard deviation, while variables with non-normal distributions are reported as median and interquartile 
range (IQR, 25th to 75th percentiles). We further investigated the relationship between clinical parameters and 
mortality using Cox proportional hazard models with stepwise selection of variables found to be significant in 
the univariate regression analysis.
Cumulative time-to-event distributions (survival) were estimated using the Kaplan–Meier method. Statisti-
cal significance was determined by the log-rank test. In all cases, P values < 0.05 were considered statistically 
significant. All statistical analyses were performed with IBM SPSS Statistics version 25.
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